11:14 AM EST - Cardiol Therapeutics Inc. : Announced that Massachusetts General Hospital has been initiated and is eligible to enroll patients in MAvERIC-Pilot, the Company's Phase II open-label pilot study, investigating the safety, tolerability, and efficacy of CardiolRx™ in patients with recurrent pericarditis. In addition to standard safety assessments, the study is designed to evaluate improvement in objective measures of this rare disease, and during an extension period, assess the feasibility of weaning concomitant background therapy including corticosteroids, while taking CardiolRx™ and to assess freedom from pericarditis recurrence. Cardiol Therapeutics Inc.
shares T.CRDL are trading up $0.04 at $1.33.
